Venous thromboembolism In clinical trials, venous thromboembolic events (VTE) reported in patients treated with abemaciclib plus an aromatase inhibitor (5%) and in patients treated with abemaciclib plus fulvestrant (5%) VTE (eg, deep vein thrombosis, pulmonary embolism, cerebral venous sinus thrombosis, pelvic venous thrombosis, subclavian and axillary vein thrombosis, inferior vena cava thrombosis) reported in patients receiving abemaciclib and fulvestrant Monitor for signs and symptoms of venous thrombosis and pulmonary embolism and appropriately treat Hepatotoxicity Increased transaminases were observed in clinical trials In patients who had grade ≥3 ALT elevation, median time-to-onset was 57 days; whereas, grade 3 neutropenia, median time...